In our experiments, downregulation of AKR1C3 restrained cell proliferation and increased the sensitivity of liver cancer cells to sorafenib, and upregulation of AKR1C3 increased cell proliferation in HCC cells. Here, AKR1C3 is linked to hepatocellular carcinoma.